WEZLANA Trademark

Trademark Overview


On Tuesday, March 7, 2023, a trademark application was filed for WEZLANA with the United States Patent and Trademark Office. The USPTO has given the WEZLANA trademark a serial number of 97826509. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, July 31, 2024. This trademark is owned by Amgen Inc.. The WEZLANA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
wezlana

General Information


Serial Number97826509
Word MarkWEZLANA
Filing DateTuesday, March 7, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, July 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 9, 2024

Trademark Statements


Goods and Servicespharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 27, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Friday, March 10, 2023NEW APPLICATION ENTERED
Monday, March 27, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 5, 2023ASSIGNED TO EXAMINER
Wednesday, December 20, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, December 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 5, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 31, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 31, 2024SOU EXTENSION 1 FILED
Wednesday, July 31, 2024SOU EXTENSION 1 GRANTED
Monday, January 6, 2025SOU TEAS EXTENSION RECEIVED